Estrogen Receptor Function: Impact on the Human Endometrium

Kun Yu, Zheng-Yuan Huang, Xue-Ling Xu, Jun Li, Xiang-Wei Fu, Shou-Long Deng, Kun Yu, Zheng-Yuan Huang, Xue-Ling Xu, Jun Li, Xiang-Wei Fu, Shou-Long Deng

Abstract

The physiological role of estrogen in the female endometrium is well established. On the basis of responses to steroid hormones (progesterone, androgen, and estrogen), the endometrium is considered to have proliferative and secretory phases. Estrogen can act in the endometrium by interacting with estrogen receptors (ERs) to induce mucosal proliferation during the proliferative phase and progesterone receptor (PR) synthesis, which prepare the endometrium for the secretory phase. Mouse knockout studies have shown that ER expression, including ERα, ERβ, and G-protein-coupled estrogen receptor (GPER) in the endometrium is critical for normal menstrual cycles and subsequent pregnancy. Incorrect expression of ERs can produce many diseases that can cause endometriosis, endometrial hyperplasia (EH), and endometrial cancer (EC), which affect numerous women of reproductive age. ERα promotes uterine cell proliferation and is strongly associated with an increased risk of EC, while ERβ has the opposite effects on ERα function. GPER is highly expressed in abnormal EH, but its expression in EC patients is paradoxical. Effective treatments for endometrium-related diseases depend on understanding the physiological function of ERs; however, much less is known about the signaling pathways through which ERs functions in the normal endometrium or in endometrial diseases. Given the important roles of ERs in the endometrium, we reviewed the published literature to elaborate the regulatory role of estrogen and its nuclear and membrane-associated receptors in maintaining the function of endometrium and to provide references for protecting female reproduction. Additionally, the role of drugs such as tamoxifen, raloxifene, fulvestrant and G-15 in the endometrium are also described. Future studies should focus on evaluating new therapeutic strategies that precisely target specific ERs and their related growth factor signaling pathways.

Keywords: G-protein-coupled estrogen receptor; endometrium; estrogen receptor α; estrogen receptor β; human.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2022 Yu, Huang, Xu, Li, Fu and Deng.

References

    1. Best Pract Res Clin Endocrinol Metab. 2006 Jun;20(2):235-44
    1. Am J Obstet Gynecol. 2007 Apr;196(4):386.e1-9; discussion 386.e9-11
    1. J Natl Cancer Inst. 1994 Apr 6;86(7):527-37
    1. SAGE Open Med. 2019 May 02;7:2050312119848247
    1. Endocrinology. 2006 Dec;147(12):5557-63
    1. Endocr Res. 2013;38(4):223-31
    1. J Reprod Fertil. 1992 Mar;94(2):363-71
    1. J Clin Oncol. 2008 Sep 1;26(25):4151-9
    1. Mod Pathol. 2000 Mar;13(3):285-94
    1. Mol Endocrinol. 1995 Nov;9(11):1441-54
    1. Cell Commun Signal. 2019 Mar 5;17(1):22
    1. Mol Cell. 2007 Sep 7;27(5):691-700
    1. Histochemistry. 1994 Nov;102(5):405-13
    1. Physiol Rev. 2001 Oct;81(4):1535-65
    1. J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):358-66
    1. Pathol Res Pract. 2020 Oct;216(10):153149
    1. Mol Hum Reprod. 2010 Oct;16(10):743-51
    1. Mol Endocrinol. 2000 Oct;14(10):1649-60
    1. J Pathol. 2011 Jun;224(2):261-9
    1. Nucl Recept Signal. 2006;4:e015
    1. Endocrinology. 2013 Jun;154(6):2222-33
    1. Proc Natl Acad Sci U S A. 2010 Nov 9;107(45):19272-7
    1. Gynecol Oncol. 2012 Nov;127(2):316-20
    1. Eur J Obstet Gynecol Reprod Biol. 2010 May;150(1):84-7
    1. Adv Protein Chem Struct Biol. 2019;116:135-170
    1. Mol Endocrinol. 2005 Nov;19(11):2696-712
    1. Trends Endocrinol Metab. 2009 Jan;20(1):8-15
    1. Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):559-64
    1. Menopause. 2005 Nov-Dec;12(6):708-15
    1. J Biol Chem. 1994 Apr 29;269(17):12940-6
    1. J Cell Sci. 1993 Dec;106 ( Pt 4):1377-88
    1. Medicina (Kaunas). 2019 Sep 07;55(9):
    1. Obstet Gynecol Int. 2013;2013:472720
    1. Mol Endocrinol. 2008 Oct;22(10):2213-4
    1. Obstet Gynecol. 1998 Jan;91(1):40-4
    1. Semin Reprod Med. 2012 Jan;30(1):39-45
    1. Gynecol Oncol. 2016 May;141(2):312-317
    1. Endocrinology. 1992 Sep;131(3):1305-12
    1. Curr Genomics. 2006;7(8):497-508
    1. Maturitas. 1996 May;23 Suppl:S37-45
    1. Genome Res. 2019 Sep;29(9):1429-1441
    1. Am J Obstet Gynecol. 2010 Dec;203(6):595.e9-16
    1. Endocr Relat Cancer. 2003 Mar;10(1):23-42
    1. Cancer Res. 2020 Mar 15;80(6):1234-1245
    1. Mol Endocrinol. 2014 Jun;28(6):899-911
    1. Mol Cell Endocrinol. 2009 Sep 24;308(1-2):9-16
    1. Horm Cancer. 2019 Jun;10(2-3):51-63
    1. Steroids. 2014 Mar;81:31-5
    1. Mol Endocrinol. 2007 Apr;21(4):829-42
    1. Cell. 2006 May 5;125(3):411-4
    1. Endocrinology. 2012 Aug;153(8):3960-71
    1. Mol Endocrinol. 2009 Oct;23(10):1544-55
    1. Clinics (Sao Paulo). 2021 Jan 20;76:e2380
    1. FEBS Lett. 1996 Aug 19;392(1):49-53
    1. Cochrane Database Syst Rev. 2017 Jan 17;1:CD004143
    1. Mol Endocrinol. 1991 Nov;5(11):1707-15
    1. Reprod Sci. 2013 Feb;20(2):129-37
    1. Mol Endocrinol. 2002 Aug;16(8):1810-27
    1. Nature. 1999 Nov 4;402(6757):93-6
    1. Mol Endocrinol. 1995 Jul;9(7):814-25
    1. Mol Cell. 2013 Oct 10;52(1):25-36
    1. Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14986-91
    1. Biol Reprod. 2009 Jan;80(1):34-41
    1. Science. 1997 Sep 5;277(5331):1508-10
    1. Endocrinology. 2013 Feb;154(2):635-45
    1. Mol Hum Reprod. 2019 Sep 1;25(9):550-561
    1. Cancer Invest. 2004;22(2):211-8
    1. Jpn J Clin Oncol. 2020 Mar 9;50(3):241-253
    1. Nature. 1997 Oct 16;389(6652):753-8
    1. J Clin Endocrinol Metab. 2009 Mar;94(3):876-83
    1. Cells. 2019 Sep 21;8(10):
    1. Endocrinology. 2011 Apr;152(4):1434-47
    1. J Biol Chem. 2000 Feb 25;275(8):5379-87
    1. Int J Gynecol Cancer. 2000 Mar;10(2):128-136
    1. Hum Reprod Update. 1997 Mar-Apr;3(2):95-100
    1. Genesis. 2009 Dec;47(12):815-24
    1. Trends Endocrinol Metab. 2001 May-Jun;12(4):152-6
    1. Proc Natl Acad Sci U S A. 2006 Nov 28;103(48):18350-5
    1. Endocrinology. 2011 Jun;152(6):2448-55
    1. Science. 1995 Nov 24;270(5240):1354-7
    1. Reprod Med Biol. 2016 Dec 05;16(1):4-20
    1. Endocrinology. 1997 Nov;138(11):4613-21
    1. Pathol Oncol Res. 2005;11(1):32-9
    1. Cell. 1998 Dec 23;95(7):927-37
    1. Int J Mol Med. 2012 Jun;29(6):1127-36
    1. Steroids. 2013 Nov;78(11):1087-91
    1. Fertil Steril. 2001 Jun;75(6):1198-205
    1. Reprod Sci. 2009 Feb;16(2):191-9
    1. Nature. 1995 Oct 5;377(6548):454-7
    1. Mol Cell Endocrinol. 2016 Jul 5;429:10-8
    1. Cancer. 2003 Nov 15;98(10):2207-13
    1. J Clin Endocrinol Metab. 2001 Mar;86(3):1370-8
    1. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3646-51
    1. Semin Reprod Med. 2004 Feb;22(1):45-50
    1. Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13311-6
    1. Science. 2002 May 31;296(5573):1642-4
    1. Endocr Rev. 2004 Dec;25(6):869-98
    1. Mol Hum Reprod. 1999 Jun;5(6):559-64
    1. J Neuroendocrinol. 2009 Mar;21(4):249-56
    1. Cancer Imaging. 2008 Jun 30;8:135-45
    1. Mol Cell Endocrinol. 2010 Apr 12;317(1-2):31-43
    1. Hum Reprod Update. 2007 Jul-Aug;13(4):405-17
    1. Mol Endocrinol. 1997 Feb;11(2):172-82
    1. Trends Endocrinol Metab. 2009 Dec;20(10):477-82
    1. Hum Reprod. 2004 Feb;19(2):352-6
    1. Mol Cell Biol. 2004 Sep;24(17):7681-94
    1. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8517-21
    1. Histol Histopathol. 2013 Nov;28(11):1491-8
    1. Menopause. 2008 Mar-Apr;15(2):233-9
    1. Lancet. 1989 Jan 21;1(8630):117-20
    1. Front Cell Dev Biol. 2014 Aug 12;2:34
    1. J Assist Reprod Genet. 2010 Aug;27(8):441-7
    1. Reprod Toxicol. 1998 May-Jun;12(3):217-21
    1. Am J Clin Exp Urol. 2014 Oct 02;2(3):169-87
    1. J Biol Chem. 2013 Jul 19;288(29):21105-21116
    1. Endocrinology. 1981 Nov;109(5):1404-13
    1. Curr Opin Cell Biol. 1997 Apr;9(2):240-6
    1. Mol Endocrinol. 1999 Oct;13(10):1672-85
    1. Mol Endocrinol. 2014 Aug;28(8):1304-15
    1. Endocrinology. 2009 Apr;150(4):1722-30
    1. J Biol Chem. 2001 Sep 28;276(39):36361-9
    1. J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):266-72
    1. Endocrinology. 2003 Jul;144(7):3159-66
    1. Gynecol Endocrinol. 2015 May;31(5):379-83
    1. J Clin Endocrinol Metab. 1997 Apr;82(4):1058-65
    1. Reprod Sci. 2012 Jul;19(7):684-93
    1. Cell. 2018 Apr 5;173(2):291-304.e6
    1. Nat Chem Biol. 2009 Jun;5(6):421-7
    1. Cell Res. 2007 Apr;17(4):277-9
    1. J Steroid Biochem Mol Biol. 2014 Sep;143:207-22
    1. JAMA. 1996 Feb 7;275(5):370-5
    1. Cancer Res. 1990 Dec 1;50(23):7677-81
    1. J Clin Endocrinol Metab. 2001 Mar;86(3):1379-86
    1. Cancer Sci. 2009 Jun;100(6):1051-61
    1. J Biol Chem. 2006 Sep 8;281(36):26683-92
    1. Br J Cancer. 2012 May 8;106(10):1682-8
    1. Front Endocrinol (Lausanne). 2015 Feb 16;6:18
    1. Nat Rev Cancer. 2006 May;6(5):360-8
    1. J Steroid Biochem Mol Biol. 1996 Nov;59(3-4):251-60
    1. Hum Reprod Update. 2015 Mar-Apr;21(2):174-93
    1. Endocrinology. 1988 Sep;123(3):1511-9
    1. Proc Natl Acad Sci U S A. 2000 May 23;97(11):5936-41
    1. J Endocrinol. 1975 Nov;67(2):275-82
    1. Essays Biochem. 2004;40:27-39
    1. Protein Sci. 2007 May;16(5):897-905
    1. Annu Rev Physiol. 2005;67:285-308
    1. Mol Endocrinol. 2002 Oct;16(10):2188-201
    1. Cell. 2015 Nov 5;163(4):960-74
    1. Reprod Sci. 2012 Jul;19(7):674-83
    1. Mol Cell Endocrinol. 2014 May 25;389(1-2):71-83
    1. Int J Gynecol Cancer. 2005 May-Jun;15(3):537-41
    1. Int J Cancer. 2004 Jul 20;110(6):783-7
    1. Mol Cell Endocrinol. 2009 Mar 25;301(1-2):74-82
    1. Development. 2000 Oct;127(19):4277-91
    1. Mol Endocrinol. 2002 Jan;16(1):70-84
    1. Science. 2005 Mar 11;307(5715):1625-30
    1. Cancer Res. 2009 Jul 1;69(13):5415-23
    1. Hum Reprod Update. 2017 Mar 1;23(2):232-254
    1. Steroids. 2003 Jan;68(1):11-9

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner